International Multicentric Study ARON-1

Recruiting Observational Study
Metastatic Renal Cell Carcinoma (mRCC)
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
1,220 (estimated)
Sponsor
Hospital of Macerata · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with fi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients aged \>18y * Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC * Histologically or radiologically confirmed diagnosis of metastatic disease * First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pemb…
Contacts

Matteo Santoni, MD, PhD

+3907332572960

mattymo@alice.it

CONTACT

Giulia Sorgentoni, PhD

giulia.sorgentoni@libero.it

CONTACT